PROTAC-mediated targeting of IKKbeta and NR4A1 for AML therapy. Maharjan CK, Liu Y, Xiao Y, Podder BR, et al. Oncogene 2026;45:3921-3934.

Read + Share

Amedeo Smart

Independent Medical Education

Maharjan CK, Liu Y, Xiao Y, Podder BR, et al. PROTAC-mediated targeting of IKKbeta and NR4A1 for AML therapy. Oncogene 2026;45:3921-3934.
PMID: 42533114